AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Hansa Biopharma AB (SS:HNSA)
34.54 SEK
+1.240 3.724%| Previous Close (in SEK) | 33.3 |
|---|---|
| Change | +1.240 3.724% |
| 52 W H/L (in SEK) | 57.300/22.000 |
| EBITDA (in SEK) | -623.305M |
| PE Ratio | -- |
| Volume | 236746 |
| Diluted Eps TTM | -11.03 |
| Total Assets (in SEK) | 1018.041M |
|---|---|
| Total Liabilities (in SEK) | 1185.917M |
| Revenue TTM (in SEK) | 189.39M |
| Cash (in SEK) | 732.06M |
| Market Cap (in SEK) | 2,002.405 M |
| Revenue Per Share TTM | 3.208 |
| Gross Profit TTM (in SEK) | 116.048M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Employees: 135
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Søren Tulstrup M.Sc | President & CEO | 1965 |
| 2. | Mr. C. Evan Ballantyne | Chief Financial Officer | 1960 |
| 3. | Dr. Christian Kjellman | Senior VP & COO | 1967 |
| 4. | Dr. Hitto Kaufmann Ph.D. | Chief Scientific Officer | 1971 |
| 5. | Ms. Eva-Maria Joed | Vice President of Finance & Administration | 1969 |
| 6. | Mr. Klaus Sindahl | VP & Head of Investor Relations | NA |
| 7. | Ms. Anne Säfström Lanner | Senior VP & Chief Human Resources Officer | 1969 |
| 8. | Mr. Emanuel Björne | VP & Head of Business Development | 1973 |
| 9. | Dr. Lena Winstedt | Head of Science | 1969 |
| 10. | Ms. Vincenza Nigro M.B.A. | VP & Head of Medical Affairs | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (SEK) | Price (SEK) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
CAMX
Camurus AB |
0.000 0.000% | 569.5 | 126.520 | 37.175 | 19.603 | 10.638 | 17.985 | 83.367 |
|
BINV
BioInvent International AB |
+0.250 0.629% | 39.75 | 0.000 | 0.000 | 69.405 | 2.723 | 46.532 | -20.588 |
|
EGTX
Egetis Therapeutics AB (publ) |
-0.120 1.805% | 6.87 | 0.000 | 8.780 | 35.237 | 7.521 | 35.014 | -7.564 |
|
VICO
Vicore Pharma Holding AB (publ) |
+0.010 0.129% | 7.77 | 0.000 | 0.000 | 17.462 | 4.794 | 14.882 | -4.300 |
Income Statement
(Currency in SEK)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -830.812M | -609.979M | -548.13M | -420.893M | -359.592M |
| Minority Interest | - | - | - | - | - |
| Net Income | -831.72M | -611.134M | -548.282M | -420.853M | -360.009M |
| Selling General Administrative | 450.492M | 337.861M | 327.269M | 202.987M | 167.31M |
| Gross Profit | 69.266M | 116.048M | 18.453M | 5.101M | 2.498M |
| Reconciled Depreciation | 19.792M | 12.054M | 8.606M | 7.666M | 7.463M |
| Ebit | -790.873M | -576.12M | -539.58M | -425.077M | -357.595M |
| Ebitda | -780.135M | -549.286M | -538.305M | -414.752M | -352.108M |
| Depreciation And Amortization | 10.738M | 26.834M | 1.275M | 10.325M | 5.487M |
| Operating Income | -790.873M | -576.12M | -539.58M | -425.077M | -357.595M |
| Other Operating Expenses | 924.967M | 730.645M | 573.458M | 431.175M | 360.959M |
| Interest Expense | 105.52M | 43.666M | 0.694M | 0.257M | 0.466M |
| Tax Provision | 1.21M | 1.155M | 0.158M | -0.04M | 0.417M |
| Interest Income | 27.992M | 21.365M | 1.151M | 1.914M | 0.076M |
| Net Interest Income | -108.968M | -34.833M | -0.627M | 0.131M | -0.348M |
| Income Tax Expense | 0.908M | 1.155M | 0.152M | -0.04M | 0.417M |
| Total Revenue | 134.094M | 154.525M | 33.878M | 6.098M | 3.364M |
| Total Operating Expenses | 860.139M | 692.168M | 558.033M | 430.178M | 360.093M |
| Cost Of Revenue | 64.828M | 38.477M | 15.425M | 0.997M | 0.866M |
| Total Other Income Expense Net | -39.939M | -33.859M | -8.55M | 4.184M | -1.997M |
| Net Income From Continuing Ops | -855.935M | -611.134M | -548.282M | -420.853M | -360.009M |
| Net Income Applicable To Common Shares | - | -609.568M | -548.282M | -420.853M | -360.009M |
Balance Sheet
(Currency in SEK)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1018.041M | 1687.406M | 1012.808M | 1434.496M | 664.236M |
| Intangible Assets | 135.817M | 46.866M | 28.761M | 31.41M | 33.348M |
| Other Current Assets | 21.543M | 0.001M | 20.889M | 5.716M | 9.393M |
| Total Liab | 1185.917M | 1084.494M | 255.235M | 192.372M | 101.421M |
| Total Stockholder Equity | -167.876M | 602.912M | 757.573M | 1242.124M | 562.815M |
| Other Current Liab | 185.046M | 154.642M | 86.01M | -0.002M | 39.335M |
| Common Stock | 55.034M | 55.034M | 46.335M | 45.895M | 41.448M |
| Capital Stock | 55.034M | 55.034M | 46.335M | 45.895M | 41.448M |
| Retained Earnings | -3302.807M | -2471.087M | -1859.953M | -1311.671M | -971.821M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | - | 0.001M |
| Cash | 732.06M | 1496.179M | 651.342M | 1139.362M | 181.697M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 320.988M | 264.713M | 171.219M | 114.203M | 94.54M |
| Current Deferred Revenue | 41.473M | 40.43M | 24.961M | 83.121M | - |
| Net Debt | 134.708M | -705.087M | -615.963M | -1134.317M | -172.238M |
| Short Term Debt | 7.503M | 7.165M | 6.888M | 4.415M | 4.632M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 866.768M | 791.092M | 35.379M | 5.045M | 9.459M |
| Other Stockholder Equity | 3080.305M | 3018.952M | 2571.064M | 2507.9M | 1412.025M |
| Property Plant Equipment | - | 35.836M | 41.705M | 9.699M | 15.144M |
| Total Current Assets | 855.151M | 1604.704M | 942.342M | 1393.387M | 615.743M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | 0M | 237.619M | 238.144M | 419.397M |
| Net Receivables | 91.756M | 107.551M | 20.958M | 6.943M | 5.257M |
| Long Term Debt | 844.903M | 762.601M | 0.722M | 0.663M | 0.73M |
| Inventory | 9.792M | 0.973M | 0.242M | 0.098M | -0.001M |
| Accounts Payable | 86.966M | 62.476M | 53.36M | 26.669M | 50.573M |
| Accumulated Other Comprehensive Income | -0.408M | 0.013M | 0.127M | -0.137M | 81.163M |
| Non Currrent Assets Other | - | - | -4.079M | -0.001M | 0.001M |
| Non Current Assets Total | 162.89M | 82.702M | 70.466M | 41.109M | 48.493M |
| Capital Lease Obligations | 21.865M | 28.491M | 35.379M | 5.045M | 9.459M |
| Long Term Debt Total | - | 783.927M | 29.213M | 1.293M | 5.557M |
Cash Flow
(Currency in SEK)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -3.88M | 229.313M | -2.399M | 182.828M | 89.125M |
| Total Cashflows From Investing Activities | - | 229.487M | -2.399M | 182.534M | 85.784M |
| Total Cash From Financing Activities | -7.545M | 1117.681M | -4.857M | 1065.906M | -8.884M |
| Net Income | -831.72M | -611.134M | -548.282M | -422.807M | -359.668M |
| Change In Cash | -764.119M | 844.837M | -488.02M | 957.665M | -257.744M |
| Begin Period Cash Flow | 1496.179M | 651.342M | 1139.362M | 181.697M | 439.441M |
| End Period Cash Flow | 732.06M | 1496.179M | 651.342M | 1139.362M | 181.697M |
| Total Cash From Operating Activities | -755.654M | -502.733M | -481.168M | -290.274M | -334.775M |
| Depreciation | 10.738M | 12.054M | 8.606M | 7.666M | 7.463M |
| Other Cashflows From Investing Activities | - | 232.644M | 0M | 182.828M | 89.212M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | 397.646M | 0M | 1070.58M | 3.186M |
| Other Cashflows From Financing Activities | -0.284M | 1449.858M | -4.857M | -0.001M | -7.646M |
| Capital Expenditures | 0.284M | 3.331M | 2.399M | 0.294M | 3.428M |
| Change In Working Capital | 11.436M | 21.432M | 2.887M | 81.276M | 10.74M |
| Other Non Cash Items | 53.892M | 74.915M | 55.621M | 0.243M | -0.556M |
| Free Cash Flow | -755.938M | -506.064M | -483.567M | -290.568M | -338.203M |
No data found
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...